首页> 外国专利> Use of HL-60-related lectins in drug delivery and detection of lectin-expressing cells

Use of HL-60-related lectins in drug delivery and detection of lectin-expressing cells

机译:HL-60相关凝集素在药物递送和表达凝集素表达细胞中的用途

摘要

Pharmaceutical compositions useful in the treatment of autoimmune conditions include as an active ingredient a soluble lectin having a molecular weight of about 14 kilodaltons or a fragment thereof. The lectin or fragment binds &bgr;-galactoside-containing moieties independent of the presence or absence of Ca+2, stimulates hemagglutination of trypsinized rabbit erythrocytes in standard lectin assays wherein the stimulation is inhibited by lactose or thiogalactoside, has an amino acid sequence containing at least one N-glycosylation site and is at least 90% homologous to the amino acid sequence shown in positions 2-135 of FIG. 1 or the relevant portions thereof. The composition is used for treatment of autoimmune conditions such as rheumatoid arthritis, myasthenia gravis, and multiple sclerosis, as well as modulating the immune response in an allergic reactions or to organ or tissue transplant rejection. The inventive composition can be combined with general immunosuppressants.
机译:可用于治疗自身免疫病的药物组合物包括作为活性成分的分子量约为14千道尔顿的可溶性凝集素或其片段。所述凝集素或片段结合Ca-Sup> +2 存在或不存在的含β-半乳糖苷的部分,在标准凝集素测定中刺激胰蛋白酶消化的兔红细胞的血凝,其中所述刺激被乳糖或硫代半乳糖苷抑制具有一个至少含有一个N-糖基化位点的氨基酸序列,并且与图1的2-135位所示的氨基酸序列具有至少90%的同源性。 1 或其相关部分。该组合物用于治疗自身免疫疾病,例如类风湿性关节炎,重症肌无力和多发性硬化,以及调节变态反应或针对器官或组织移植排斥的免疫反应。本发明的组合物可以与一般的免疫抑制剂组合。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号